According to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a primary dose (2-dose) schedule, and a heterologous booster dose for subjects who have previously received 2 doses of the two commonly administered covid vaccines in India including Covishield and Covaxin.
